Yu Shuangqing, Ph.D. in Immunology, Director of the Department of Bioanalysis, Genecradle Therapeutics Inc. I was awarded a Ph.D. from the Institute of Viral Disease Prevention and Control of the Chinese Center for Disease Control and Prevention in 2008 and have been engaged in the research and development of HIV vaccines based on viral vectors for 15 years (2001-2015). I began to research and develop gene therapy drugs based on AAVs in 2016, involving CMC, clinical pharmacology, and bioanalysis of AAV vectors.
Yu Shuangqing, Ph.D. in Immunology, Director of the Department of Bioanalysis, Genecradle Therapeutics Inc. I was awarded a Ph.D. from the Institute of Viral Disease Prevention and Control of the Chinese Center for Disease Control and Prevention in 2008 and have been engaged in the research and development of HIV vaccines based on viral vectors for 15 years (2001-2015). I began to research and develop gene therapy drugs based on AAVs in 2016, involving CMC, clinical pharmacology, and bioanalysis of AAV vectors.